RT Journal Article
T1 Basophil Activation Test Utility as a Diagnostic Tool in LTP Allergy
A1 Cañas, José Antonio
A1 Pérez-Sánchez, Natalia Isabel
A1 Palomares, Francisca
A1 Molina, Ana
A1 Bartra, Joan
A1 Torres-Jaén, María Josefa
A1 Gómez, Francisca
A1 Mayorga Mayorga, Cristobalina
K1 Citometría de flujo
AB Plant-food allergy is an increasing problem, with nonspecific lipid transfer proteins (nsLTPs) triggering mild/severe reactions. Pru p 3 is the major sensitizer in LTP food allergy (FA). However, in vivo and in vitro diagnosis is hampered by the need for differentiating between asymptomatic sensitization and allergy with clinical relevance. The basophil activation test (BAT) is an ex vivo method able to identify specific IgE related to the allergic response. Thus, we aimed to establish the value of BAT in a precise diagnosis of LTP-allergic patients. Ninety-two individuals with peach allergy sensitized to LTP, Pru p 3, were finally included, and 40.2% of them had symptoms to peanut (n = 37). In addition, 16 healthy subjects were recruited. BAT was performed with Pru p 3 and Ara h 9 (peanut LTP) at seven ten-fold concentrations, and was evaluated by flow cytometry, measuring the percentage of CD63 (%CD63+) and CD203c (%CD203chigh) cells, basophil allergen threshold sensitivity (CD-Sens), and area under the dose–response curve (AUC). Significant changes in BAT parameters (%CD63+ and %CD203chigh) were found between the controls and patients. However, comparisons for %CD63+, %CD203chigh, AUC, and CD-Sens showed similar levels among patients with different symptoms. An optimal cut-off was established from ROC curves, showing a significant positive percentage of BAT in patients compared to controls and great values of sensitivity (>87.5%) and specificity (>85%). In addition, BAT showed differences in LTP-allergic patients tolerant to peanut using its corresponding LTP, Ara h 9. BAT can be used as a potential diagnostic tool for identifying LTP allergy and for differentiating peanut tolerance, although neither reactivity nor sensitivity can distinguish the severity of the clinical symptoms.
PB IOAP-MPDI
YR 2022
FD 2022-04-29
LK https://hdl.handle.net/10630/24337
UL https://hdl.handle.net/10630/24337
LA eng
NO Cañas JA, Pérez-Sánchez N, Lopera-Doblas L, Palomares F, Molina A, Bartra J, Torres MJ, Gómez F, Mayorga C. Basophil Activation Test Utility as a Diagnostic Tool in LTP Allergy. International Journal of Molecular Sciences. 2022; 23(9):4979. https://doi.org/10.3390/ijms23094979
NO Partial funding for open access charge: Universidad de Málaga. This research was funded by grants from the “Instituto de Salud Carlos III” (ISCIII) of the Ministry of Economy and Competitiveness: PI17/01318, PI18/00288, PI21/00346, AC18/00031; RETICS ARADyAL (RD16/0006/0001, RD16/0006/0007); Sara Borrell (CD20/00085) Program; RICORS (RD21/0002/0008, RD21/0002/0058); and Next Generation EU funds. Andalusian Regional Ministry of Health (PE-0039-2018, RH-0085-2020, and PI-0099-2020), Senior Clinical Researcher Program (B-0005-2019), and Nicolas Monardes Program (RC-0004-2021). Roche Pharma S.A. “Stop Fuga de Cerebros” Program (SFC-0002-2020). Grants were co-funded by the European Regional Development Fund (ERDF). “Una manera de hacer Europa” “Andalucía se mueve con Europa”.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026